This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Changes in Iron Markers Following Iron Loading in Hemodialysis Patients

This study has been completed.
Information provided by:
Papageorgiou General Hospital Identifier:
First received: March 28, 2006
Last updated: March 12, 2007
Last verified: September 2006
The purpose of this study is to describe alterations of serum ferritin, transferrin saturation, soluble transferrin receptor, % hypochromic erythrocytes, % reticulocytes, reticulocyte hemoglobin content after iron loading in hemodialysis patients.

Condition Intervention Phase
Anemia in Chronic Renal Disease Drug: iron sucrose Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Official Title: Phase IV Study of Iron Indices' Kinetics in Hemodialysis Patients

Resource links provided by NLM:

Further study details as provided by Papageorgiou General Hospital:

Primary Outcome Measures:
  • Ferritin alterations after iron loading at six and twelve weeks from the beginning of iron loading.

Secondary Outcome Measures:
  • All iron indices' alterations during twelve weeks from the beginning of iron loading.

Estimated Enrollment: 160
Study Start Date: September 2005
Estimated Study Completion Date: January 2007

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • hemodialysis for three months minimum
  • stable epoetin dose for two months minimum
  • serum ferritin concentration < 1000 ng/ml
  • transferrin saturation < 50%
  • parathormone concentration < 800 pg/ml

Exclusion Criteria:

  • hemoglobin concentration > 13g/dl
  • serum ferritin concentration < 20 ng/ml
  • vitamin B12 and/or folic deficiency
  • other hematologic disease than anemia
  • cancer
  • hypothyroidism
  • infectious disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00308490

Papageorgiou General Hospital
Thessaloniki, Greece, 56429
Sponsors and Collaborators
Papageorgiou General Hospital
Principal Investigator: Efstathios Mitsopoulos, MD Papageorgiou General Hospital
  More Information Identifier: NCT00308490     History of Changes
Other Study ID Numbers: 48/31-1-2005
Study First Received: March 28, 2006
Last Updated: March 12, 2007

Additional relevant MeSH terms:
Renal Insufficiency, Chronic
Kidney Failure, Chronic
Renal Insufficiency
Kidney Diseases
Urologic Diseases
Ferric oxide, saccharated
Trace Elements
Growth Substances
Physiological Effects of Drugs
Hematinics processed this record on July 19, 2017